NCT01470937

Early Diabetes Intervention Program

• Status: Completed
• Phase: Phase 4
• Study type: Interventional
• Enrollment: 219 (actual)
• Sponsor: Indiana University School of Medicine · Academic / Other
• Sex: All
• Age: 25 Years – 80 Years
• Healthy volunteers: Not accepted

Summary

This is an evaluation of the effect of acarbose to delay worsening of fasting glucose control in early Type 2 diabetes mellitus.

Detailed description

A double blind, randomized, placebo-controlled clinical trial of acarbose in subjects with type 2 diabetes (an FDA-approved indication). Subjects were identified who had diabetes by glucose tolerance test criteria but non-diabetic fasting glucose concentrations. Treatment interventions were assessed for their ability to delay worsening of fasting glucose control.

Conditions

• Type 2 Diabetes Mellitus

Interventions

Type	Name	Description
DRUG	Acarbose	acarbose 100 mg PO once daily
DRUG	Placebo	acarbose placebo

Timeline

• Start date: 1998-02-01
• Primary completion: 2004-09-01
• Completion: 2004-09-01
• First posted: 2011-11-11
• Last updated: 2011-11-11

Locations

1 site across 1 country: United States